Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis
Ludwig Kappos(University Hospital of Basel), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Olaf Stüve(Southwestern Medical Center), Hans‐Peter Hartung(The University of Sydney), Erik Wallström(Novartis (Switzerland)), David K.B. Li(University of British Columbia), Sophie Arnould(Novartis (Switzerland)), Brian Hunter(Novartis (Switzerland)), Mark S. Freedman(University of Ottawa), Tjalf Ziemssen(University Hospital Carl Gustav Carus), Bernhard Hemmer(Munich Cluster for Systems Neurology)
Cited by 103
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k